Oncology Corporate Profile
Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients. As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer. Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offers an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy.
|BioSpeciFx®||molecular screening test||BioSpeciFx® is a select group of clinically relevant molecular tests associated with drug response and patient prognosis.|
|ChemoFx®||drug response marker||ChemoFx® was designed to show chemotherapy resistance and sensitivity over a broad range of agents and tumor types, including ovarian, breast, endometrial, cervical, lung and colorectal.|
|GeneFxSM Colon||microarray-based gene signature||GeneFxSM Colon is a microarray-based gene signature developed for stage II colon cancer patients from FFPE tissue. GeneFxSM Colon is performed on a small amount of tissue, removed during surgery or a biopsy. The signature identifies patients at higher risk of recurrence within 5 years following initial surgery.|
View additional information on commercial products here »
This company does not have any pipeline products